Nasdaq Grants Alberton Acquisition More Time to Comply with Listing Rule

CM Life Sciences is in a pending $793 million merger with clinical data company Sema4.

In its review of the matter, the SPAC said because its warrants include a cash settlement feature that could arise in certain events, such as a tender or exchange offer accepted by more than 50 percent of shareholders, shifting warrants to the liabilities side of the balance sheet was the prudent move.